Brief: Relmada Therapeutics Announces Dosing Of First Patient In Relight, A Phase 3 Trial Of Rel-1017 For The Adjunctive Treatment Of Major Depressive Disorder
23/08/2023 12:30
Aug 23 (Reuters) -
* RELMADA THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN
RELIGHT, A PHASE 3 TRIAL OF REL-1017 FOR THE ADJUNCTIVE
TREATMENT OF MAJOR DEPRESSIVE DISORDER
Source text for Eikon: ID:nPn4BXwsLa
Further company coverage: RLMD.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Relmada Therapeutics
See all newsRelmada Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Relmada Therapeutics Q2 EPS USD -0.11
Relmada Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia As Chief Business Officer
Brief: Relmada Therapeutics - Increases Authorized Common Stock To 200 Million Shares From 150 Million